Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 52-61

  Li, Chien Te ^a,b   Marek, Magdalena ^c   Guclu, Salih Z ^d   Kim, Younseup ^e   Meshref, Mohamed ^f   Qin, Shukui ^g   Kadziola, Zbigniew ^h   Krejcy, Kurt ^h   Altug, Sedat ⁱ  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c Department of Lung Cancer Chemotherapy   (Poland)

^d Izmir Chest Diseases and Surgery Training Hospital   (Turkey)

^e Dankook University College of Medicine   (South Korea)

^f CAIRO UNIVERSITY   (Egypt)

^g Nanjing Bayi Hospital   (China)

^h Eli Lilly Regional Operations   (Austria)

ⁱ Medical Department   (Turkey)

Author keywords

NSCLC; Observational; Predictive modeling; Prognostic factors; Smoking

Indexed keywords

CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; BLEEDING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; PREDICTIVE VALUE; SIDE EFFECT; SMOKING; SUPERIOR CAVA VEIN OBSTRUCTION; SURVIVAL PREDICTION; SURVIVAL TIME; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 81155159343     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.52     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
2. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83: 18-29.
3. Araujo A, Ribeiro R, Azevedo I, et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist. 2007; 12: 201-210.
4. Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol. 2006; 7: 499-507.
5. Ginsberg RJ, Vokes EE, Rosenzweig K. Non-small cell lung cancer. In: DeVita VT, et al, eds. Cancer: Principles and Practice of Oncology; 6th ed. Philadelphia: Lippincott-Raven; 2001: 925-983.
6. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999; 91: 1194-1210.
7. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol. 2002; 3: 461-469.
8. Yuspa SH, Shields PG. Etiology of cancer: chemical factors. In: DeVita VT, et al, eds. Cancer: Principles and Practice of Oncology; 6th ed. Philadelphia: Lippincott-Raven; 2001: 179-193.
9. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986; 4: 702-709.
10. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986; 4: 1604-1614.
11. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991; 9: 1618-1626.
12. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of st age I V non-small cell lung cancer. Chest. 2003; 123 (1 Suppl): 226S-243S.
13. Gregorc V, Ludovini V, Pistola L, et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2003; 39: 41-48.
14. Murakami I, Hiyama K, Ishioka S, et al. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. Clin Cancer Res. 2000; 6: 526-530.
15. Rosell R, Fossella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer. 2002; 38 (Suppl 4): 43-49.
16. van Houwelingen HC. Validation, calibration, revision and combination of prognostic survival models. Stat Med. 2000; 19: 3401-3415.
17. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002; 122: 1037-1057.
18. Ahuja R, Weibel SB, Leone FT. Lung cancer: the oncologist's role in smoking cessation. Semin Oncol. 2003; 30: 94-103.
19. Toh CK, Wong EH, Lim WT, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004; 126: 1750-1756.
20. Tsao AS, Liu D, Lee JJ, et al. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006; 106(11): 2428-2436.
21. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551.
22. Nguyen B, Paul S, Posther K, et al. The effect of smoki ng hi story on survival outcome: An exploratory analysis of a phase III study of gemcitabine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2006; 24(18S): Abstract7141.
23. Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005; 23: 175-183.
24. Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006; 107: 781-792.
25. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol. 1995; 13: 1221-1230.
26. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004; 22: 330-353.
27. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99: 847-857.
28. Wang Y, Zhang D, Zheng W, et al. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer. 2008; 112: 1325-1336.
29. Guzman LM, Koriyama C, Akiba S, et al. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile. Biol Res. 2007; 40: 365-372.
30. Li J, Zhang Z, Dai Z, et al. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer. Neoplasia. 2003; 5: 362-366.